Iradimed (NASDAQ:IRMD) Issues Q2 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) updated its second quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of 0.410-0.440 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $19.7 million-$19.9 million, compared to the consensus revenue estimate of $19.8 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Trading Down 2.2 %

NASDAQ IRMD opened at $52.30 on Tuesday. Iradimed has a 12 month low of $41.60 and a 12 month high of $63.29. The firm has a market capitalization of $664.99 million, a PE ratio of 34.87 and a beta of 0.91. The business’s 50-day moving average price is $52.26 and its two-hundred day moving average price is $54.37.

Iradimed (NASDAQ:IRMD) last released its earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a net margin of 26.26% and a return on equity of 24.12%. The firm had revenue of $19.39 million for the quarter, compared to analyst estimates of $19.09 million. As a group, analysts forecast that Iradimed will post 1.66 earnings per share for the current fiscal year.

Iradimed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 5th. Investors of record on Monday, February 24th were given a dividend of $0.17 per share. This is a positive change from Iradimed’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend was Monday, February 24th. This represents a $0.68 annualized dividend and a dividend yield of 1.30%. Iradimed’s dividend payout ratio is presently 45.33%.

Wall Street Analyst Weigh In

IRMD has been the topic of a number of research reports. StockNews.com upgraded shares of Iradimed from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Roth Mkm reaffirmed a “buy” rating and issued a $72.00 target price (up from $60.00) on shares of Iradimed in a research report on Friday, February 14th.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.